For example, SMAD7 activates the TAK1-p38 MAPK pathway in human prostate cancer cells (Edlund et al., 2003), whereas Smad6 inhibits TGF-β1-induced activation of this pathway (Jung et al., 2013). Here, MAP3K7 is linked to prostate carcinoma.